Skip to main content

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Enrolling by invitation · Phase 3 · NCT05667493

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
45
Sites paid
48
Planned or actual enrollment
1,400

About the trial

Sponsor
Ionis Pharmaceuticals, Inc. (with AstraZeneca)
Tested
Eplontersen (drug)
Dates
Started 2022-11-30; completion 2029-08
Results posted
Not yet

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ionis Pharmaceuticals, Inc. reported $1.7M in research payments for this study in 2025 (247 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.